SCA
NVCR icon

Snowden Capital Advisors’s NovoCure NVCR Stock Holding History

Snowden Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,524
Closed -$258K – 1181
2022
Q4 		$258K Buy
3,524
+202
+6% +$15.2K 0.01% 978
2022
Q3 		$252K Buy
+3,322
New +$259K 0.01% 960
2022
Q1 		– Sell
-9
Closed – – 1711
2021
Q4 		$0 Buy
+9
New +$903 ﹤0.01% 2106

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Snowden Capital Advisors's NVCR Position: Q1 2023 in Review

Snowden Capital Advisors sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 3,524 shares — an estimated $258K sold.

Snowden Capital Advisors first reported a position in NVCR in Q4 2021 and held it in 3 quarters. The position peaked at $258K in Q4 2022. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • Snowden Capital Advisors reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • Snowden Capital Advisors sold 3,524 NovoCure shares in Q1 2023, an estimated $258K.
  • Snowden Capital Advisors first reported a position in NovoCure in Q4 2021 and held it in 3 quarters.
  • Snowden Capital Advisors's NovoCure position peaked at $258K in Q4 2022.
  • 295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Snowden Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.